
One of Genmab’s most important products, leukemia drug Arzerra (ofatumumab), sold for a total of GBP 17.8m, or about USD 28.8m, in Q3 2013. Genmab’s licensing deal with partner GSK, meaning that Genmab receives royalties of at least 20 % from the sale of the drug, provides for a payment of about USD 5.76m for the Danish company for the quarter, Genmab reveals in a stock market release.
Although the payment of USD 5.76m is identical to the one Genmab received the previous quarter, sales of Arzerra have actually improved.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app